PKLR: A Potential Drug Target for Pyruvate Metabolism (G5313)

Target Name: PKLR

NCBI ID: G5313

PKLR

PKLR: A Potential Drug Target for Pyruvate Metabolism

Pyruvate kinase (PKLR) is a protein that plays a critical role in the metabolism of pyruvate, a key intermediate step in the citric acid cycle (also known as the Krebs cycle or TCA cycle). The PKLR enzyme catalyzes the conversion of pyruvate to acetyl-CoA, which is then used to produce fatty acids and carbon dioxide. This enzyme is located in the cytoplasm of eukaryotic cells and is involved in various cellular processes, including energy metabolism, cell growth, and cell signaling.

PKLR is a member of the PKA family of enzymes, which includes several isoforms, including isoform 1 (PKLR1), isoform 2 (PKLR2), and isoform 3 (PKLR3). These isoforms differ in their catalytic specificity and stability. PKLR1 is the most abundant isoform, and it is also the most well-studied.

PKLR1 is a 26 kDa protein that is expressed in various tissues and cells, including muscle, heart, liver, and kidney. It is involved in the citric acid cycle and fatty acid oxidation. PKLR1 has been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

One of the unique features of PKLR1 is its catalytic activity. PKLR1 has a highly catalytic active site, which allows it to efficiently convert pyruvate to acetyl-CoA. This conversion is critical for the production of fatty acids, which are essential for cellular signaling and energy production. In addition, PKLR1 has a highly stable active site, which allows it to maintain its catalytic activity even in the presence of inhibitors.

PKLR1 has also been shown to play a role in the regulation of cellular processes that are independent of its catalytic activity. For example, studies have shown that PKLR1 can inhibit the activities of other enzymes involved in cell signaling pathways, such as tyrosine kinase and G protein-coupled receptors. This suggests that PKLR1 may have a unique mechanism of action that is independent of its catalytic activity.

Due to its role in the regulation of cellular processes, PKLR1 has been identified as a potential drug target. Several studies have shown that inhibitors of PKLR1 can be effective in treating various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. For example, studies have shown that inhibitors of PKLR1 have been effective in treating cancer by inhibiting the production of fatty acids, which can contribute to tumor growth. In addition, inhibitors of PKLR1 have been shown to be effective in treating neurodegenerative diseases by regulating the production of acetyl-CoA, which is involved in the production of neurotransmitters.

In conclusion, PKLR is a protein that plays a critical role in the metabolism of pyruvate and is involved in various cellular processes. It is a potential drug target due to its role in the regulation of cellular processes and its ability to inhibit the production of fatty acids, which can contribute to the development of various diseases. Further research is needed to fully understand the mechanism of action of PKLR and to develop effective inhibitors for this protein.

Protein Name: Pyruvate Kinase L/R

Functions: Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis

The "PKLR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PKLR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets